Advertisement

Reactions Weekly

, Volume 1747, Issue 1, pp 210–210 | Cite as

Nivolumab

Various toxicities: 7 case reports
Case report
  • 32 Downloads

Reference

  1. Stroud CRG, et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. Journal of Oncology Pharmacy Practice 25: 551-557, No. 3, 2019. Available from: URL: http://doi.org/10.1177/1078155217745144 - USACrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations